Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

FDA warning letter puts Ipca Labs under fire for widespread data manipulation

A new FDA warning letter for three Ipca Laboratories plants shows that data manipulation and falsification were rampant there--and enforced by senior managers in the quality-control unit to keep product supply flowing.

Sanofi scarce on turnaround details, but left a few needles in the Q4 haystack

If you expected a catalog of detail on Sanofi's turnaround plans with Tuesday's earnings release, think again.

Sanofi's outlook less than sunny as key diabetes franchise continues to sag

Sanofi delivered a good-news, bad-news set of fourth-quarter results: Earnings better than expected and solid growth in emerging markets, but shortfalls in overall revenue and operating profits. Its follow-up to big-selling Lantus, Toujeo, beat projections, but its long-anticipated cholesterol fighter, Praluent, brought in just a few million euros.

Top exec exits as Pfizer redraws org chart for post-megamerger future

Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.

Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad

It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.

J&J chief shells out $9M for Manhattan condo

Johnson & Johnson CEO Alex Gorsky and his wife have a new Manhattan pad. The Gorskys laid out $9 million--more than the asking price--for a condo on Riverside Drive.

Media-magnet hearing on Capitol Hill gets underway, with Valeant, Turing under spotlight

Pharma eyes are watching Capitol Hill on Thursday, where drug-price hikes will go on trial in a much-publicized congressional committee hearing. Valeant interim CEO Howard Schiller and ex-Turing Pharmaceuticals chief Martin Shkreli will get a grilling, though Schiller is the only one expected to answer any questions.

Patent losses looming, AZ fights back with Brilinta, diabetes and China

AstraZeneca is suffering from a new round of patent losses, and that suffering will only worsen. Already hurting from generic competition to its former top-seller, Nexium, the London-based company will fall off another patent cliff this year--Crestor--and faces still another in Seroquel XR next year.

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises--Januvia and Remicade--slid, dragging overall sales below analyst estimates at $10.2 billion. One bright spot? A lower tax rate managed to boost Merck's earnings above analyst estimates at 93 cents per share.

Novo Nordisk outstrips rivals with 8% growth, but lower profits target spooks investors

Novo Nordisk's bad news: It's lowering its long-term forecast for profits. Good news? Those forecasts are still at 10% annual growth, on average, which beats its Big Pharma rivals, no contest.